Target geographies covered.
A leading global pharmaceutical company entering into the oncology segment.
The client was looking for an opportunity to characterize the Glioblastoma Multiforme (GBM) market in the US and UK, thus enabling them to take a business decision on an in-licensing opportunity for an early stage molecule.
SG Analytics consulted the client in approach selection and performed a critical assessment of the GBM therapeutics market through extensive secondary research. SG Analytics' experts gathered all relevant information and presented the following insights in a structured report:
Disease overview - pathophysiology, etiology and risk factors.
Epidemiology – diagnosis, incidence (current and forecasted), prevalence, mortality, and burden of the disease.
Disease management – current and evolving treatment regime.
Competitive landscape – key players and pipeline analysis.
Unmet need analysis.
SG Analytics delivered a comprehensive analysis of the GBM therapeutics market and enabled the client to estimate the molecule’s commercial potential.
The report facilitated a well-organized approach towards potential collaboration and helped the client take an informed, data-backed decision.